BIOSPECTATOR: RudaCure, 'Rac1 inhibitor' dry eye disease treatment — "Domestic Phase 1 trial in H2"
CEO Yongho Kim of RudaCure stated, "Our dry eye disease treatment candidate, the Rac1 inhibitor 'RCI001 (8-oxo-2'-deoxyguanosine),' showed significant corneal damage recovery and increased tear secretion compared to the control drug from day 5 of administration in mouse model studies, with no side effects observed even after 5–6 weeks of administration," adding, "We expect it to fulfill the unmet medical needs of existing drugs that required long-term administration."
Additionally, RudaCure is preparing a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for Phase 2 clinical trials, targeting IND submission by the end of this year or early next year.
RudaCure was founded in 2018 by Professor Yongho Kim of Gachon University College of Medicine and raised KRW 6 billion through Series A in May. In addition to RCI001, RudaCure is currently conducting preclinical research on TRPV1 antagonist 'RCI002' as a neuropathic pain treatment.
